FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 466
(Updated 04/27/2022)
To determine the applicant’s eligibility for certification, the AME must review a current, detailed
Clinical Progress Note generated from a clinic visit with the treating physician or specialist no
more than 90 days prior to the AME exam. If the applicant meets ALL the acceptable
certification criteria listed below, the AME can issue. Applicants for first- or second-class
must provide this information annually; applicants for third-class must provide the information
with each required exam.
AME MUST REVIEW ACCEPTABLE CERTIFICATION
CRITERIA
[ ] Yes
The pathology showed:
Carcinoma in Situ (Tis), Stage 0;
Ductal Carcinoma in Situ (DCIS);
Lobular Carcinoma in Situ (LCIS);
Paget disease of the breast (Tis)
The treating physician’s current, detailed Clinical [ ] Yes
Progress Note verifies:
• Condition is stable with no spread or reoccurrence
and no evidence of disease (NED).
• Radiation therapy (if any) is completed
• If surgery has been performed, the airman is off
all pain medication(s), has made a full recovery,
and has been released by the surgeon.
• The airman is back to full, unrestricted activities
and
Any evidence of: [ ] No
• Stage IA or higher
• Invasive or metastatic disease
• Use of chemotherapy for this condition at any time
Current medication(s): [ ] None; or
Approved medications include:
tamoxifen (Nolvadex); [ ] An approved medication that is
Aromatase inhibitors: anastrozole (Arimidex), being
letrozole (Femara), or exemestane (Aromasin) well tolerated with no side effects
Notes: If it has been 5 or more years since the airman has had any treatment (surgery or radiation) for this condition, has
no history of metastatic disease, and no reoccurrence, CACI is not required. Note this in Block 60.
AME MUST NOTE in Block 60 one of the following:
[ ] CACI qualified breast cancer (Documents do not need to be submitted to the FAA.)
[ ] Has current OR previous SI/AASI but now CACI qualified breast cancer.
[ ] NOT CACI qualified breast cancer. I have deferred. (Submit supporting documents.)
Shown as extracted from the FAA PDF, without paraphrasing. Tables and forms may lose their layout. Underlined references open the Guide location they name.
Related guidance
Navigation aids drawn from the Guide's own structure and explicit cross-references. They are not medical or certification decisions.
FAA Guide for Aviation Medical Examiners, Version 10/28/2026, page 466. AME Copilot is an independent reference tool, not affiliated with or endorsed by the FAA. The FAA AME Guide is the authoritative source.
Refers to this section on page 643 · page 643
“….113(b)(c); 67.213(b)(c); 67.313(b)(c) II. MEDICAL HISTORY: Item 48. General Systemic The use of medications below may be acceptable if there are no side effects (localized or syst…”